IntelliGen AI, an artificial intelligence (AI) start-up founded in Hong Kong, is positioning itself as a competitor to Google DeepMind in the field of drug discovery, as the city increasingly seeks to bolster its AI capabilities.In an interview with the Post, founder and president Ronald Sun expressed confidence that IntelliGen AI could soon compete globally with Isomorphic Labs, a spin-off of DeepMind, in leveraging AI for drug screening and design.“For generative science, new breakthroughs...